FDA Special Protocol Assessment

From Wikipedia, the free encyclopedia

A Special Protocol Assessment (SPA) is a declaration from the Food and Drug Administration that an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval.

[edit] External links

• Delcath Systems, Inc. receives SPA
• BioCryst Pharmaceuticals, Inc. receives SPA

[edit] References

• FDA definition